Cue Biopharma is trading 5.5% down at $23.01 on October 6, 2026; biotech-sector weakness may be contributing, though no clear company-specific catalyst was identified.

  • The supplied sector context shows XBI down 2.50%, and market data also show the biotech ETF lower during the session.
  • Major indexes were higher, while an October 6 report documented the drop without identifying a specific catalyst.